Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970996 · ClinicalTrials.gov registry record · Phase 1
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00970996: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00970996 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00970996, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to patients with metastatic melanoma. Primary Objective: * The primary objective of the Phase I is to determine the toxicity, safety and the maximum tolerated dose maximum tolerated dose of Abraxane in combination with Cisplatin, Temozolomide, interleukin-2 and interferon a2b in patients with metastatic melanoma. Secondary Objectives: * To assess responses to the combination. * To evaluate the duration of response and the overall survival. * To determine the effectiveness in delaying the appearance of Central Nervous System disease.
Interventions
- DRUG Cisplatin
- DRUG Temozolomide
- BIOLOGICAL Interleukin-2
- DRUG Abraxane
- BIOLOGICAL Interferon alpha 2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00970996
The ClinicalTrials.gov registry entry for NCT00970996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00970996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00970996 about?
NCT00970996 is a clinical study titled "Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma". The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to patients with metastatic melanoma. Primary Objective: * The primary objectiv...
What is the current status of trial NCT00970996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00970996?
The interventions under investigation include: Cisplatin (DRUG), Temozolomide (DRUG), Interleukin-2 (BIOLOGICAL), Abraxane (DRUG), Interferon alpha 2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00970996?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.